Teva to continue laquinimod development despite EMA

Cabinet approves budget cut despite Smotrich's opposition

Europe's Committee for Medicinal Products for Human Use: The risk-benefit profile of laquinimod is not favorable at this time.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) and Active Biotech AB (OMX: ACTI), which are jointly developing laquinimod (Nerventra) for the treatment of multiple sclerosis, will continue development of the drug. They announced on Friday that they were committed to laquinimod's clinical development program despite a negative opinion by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

EMA defers decision on Teva's Laquinimod

Teva: Laquinimod reduces brain damage in MS patients

Teva to reduce size of board

Teva petitions US Supreme Court over Copaxone ruling

Teva acquires NuPathe for $144m

The CHMP has concluded that the risk-benefit profile of Nerventra is not favorable at this time. In accordance with European regulations, Teva and Active Biotech intend to request a re-examination of the CHMP opinion. Teva and Active Biotech say they are focusing on evaluating the CHMP�s review and will continue to liaise closely with the EMA in working to make Nerventra available as a new treatment option for patients with relapsing-remitting multiple sclerosis in Europe.

Published by Globes [online], Israel business news - www.globes-online.com - on January 26, 2014